Abstract:OBJECTIVE:To investigate whether the polymorphism of osteoprotegerin (OPG) gene is associated with the change of BMD (bone mineral density) after alendronate therapy in postmenopausal women with osteoporosis and determine the correlation between genotypes and therapeutic effect.METHODS:Eighty postmenopausal osteoporotic patients were recruited with an average age of (64.2 +/- 7.7) years old. Every patient took oral alendronate (Fosamax) 70 mg weekly and Caltrate 600 mg daily for 12 months. At pre- and post-treatment, BMD was measured at lumbar spine 2 - 4 and hip sites. PCR-RFLP was performed for three polymorphisms at the promoter site of OPG gene (A163G, T245G and T950C).RESULTS:One-year therapy was accomplished in 67 patients. Patients with G allele (genotype AG and GG) of site A163G, the baseline BMD of vertebral L2-4, inter-troche and total hip were lower than genotype AA [(0.732 +/- 0.113) g/cm(2) vs (0.819 +/- 0.157) g/cm(2), (0.775 +/- 0.101) g/cm(2) vs (0.843 +/- 0.124) g/cm(2) and (0.667 +/- 0.105) g/cm(2) vs (0.725 +/- 0.091) g/cm(2)]. Patients with G allele (genotype TG and GG) of site T245G, baseline BMD of vertebral L2-4, inter-troche and total hip were lower than genotype TT [(0.723 +/- 0.111) g/cm(2) vs (0.819 +/- 0.155) g/cm(2), (0.776 +/- 0.102) g/cm(2) vs (0.840 +/- 0.124) g/cm(2) and (0.670 +/- 0.109) g/cm(2) vs (0.721 +/- 0.091) g/cm(2)]. After one-year therapy, at site A163G, the percentage of BMD change at inter-troche was higher in genotype AA than in genotypes AG and GG [2.50 (3.47)% vs 0.88% (3.47%)%, P = 0.014]. While at site T245G, the percentage of BMD change at inter-troche and total hip were higher in genotype TT than in genotype TG and GG 2.50% (3.47%) vs 0.61% (3.31%), P = 0.011; 2.72% (2.68%) vs 0.89 (3.01%), P = 0.046].CONCLUSION:The G allele of sites A163G and T245G may be the risk allele of postmenopausal osteoporosis. Furthermore, patients with genotypes AA (A163G) and (T245G) show a better therapeutic effect to alendronate.

[Effect of Osteoprotegerin Gene Polymorphism on Bone Mass in Postmenopausal Women].

EFFECT OF OSTEOPROTEGERIN GENE POLYMORPHISM ON BONE MASS IN PREMENARCHE GIRLS

Association of the G.27563g>a Osteoprotegerin Genetic Polymorphism with Bone Mineral Density in Chinese Women.

[Osteoprotegerin Gene Polymorphism and Therapeutic Response to Alendronate in Postmenopausal Women with Osteoporosis].

Association between T245G polymorphisms in the osteoprotegerin gene and bone mineral density in elderly individuals

The Study of the Association Between T950C Gene Polymorphism in the Promoter Region of Osteoprotegerin and Bone Mineral Density in Postmenopausal Women

Association between A163G polymorphism of the osteoprotegerin gene and bone mineral density in the Chinese elderly from Beijing Area

Study of the Impact of Candidate Genes on Bone Mineral Density in Postmenopausal Women

The Influence of Lys3Asn Polymorphism in the Osteoprotegerin Gene on Bone Mineral Density in Chinese Postmenopausal Women

Regional differences of the single T149-C mutation polymorphism in the promoter region of osteoprotegerin gene

Association between the G1181C polymorphism of osteoprotegerin gene and bone mineral density in postmenopausal women

[Study on the Correlation Between the Polymorphism of --1997g/t Site of Collagen I Alpha 1 Gene and Bone Mineral Density in Postmenopausal Women].

Association of G209A and T245G polymorphisms of osteoprotegerin gene promoter with bone mineral density and bone turnover in females

Associations of Serum Osteocalcin and Polymorphisms of the Osteocalcin Gene with Bone Mineral Density in Postmenopausal and Elderly Chinese Women.

Effect of PTH gene polymorphism on bone mineral density in normal females

Candidate Genes of Osteoporosis(er,il-6,Colia1) in Postmenopausal Women

Effect of estrogen receptor genotypes on bone mineral density in postmenopausal women

Relationship Between Bone Mineral Density and Polymorphism of the Estrogen Receptor Gene in Healthy Postmenopausal Women in China

Association between T950C and A163G polymorphism of the osteoprotegerin gene and bone mineral density in elderly type 2 diabetic patients

Relationship between estrogen receptor polymorphism and bone mineral density of postmenopausal women in Guanzhong area of Shaanxi Province

Effect of osteoprotegerin and transforming growth factor-βon bone turnover rate in women